Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Pang

Showing results (691-700 of 701) with videos related to

Pageof 71
Sort By:
Antimicrobial Agents and Chemotherapy|January 31, 2018
Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in ChinaQingfeng Wang, Yu Pang, Wei Jing, et al.
Orphanet Journal of Rare Diseases|August 15, 2024
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysisYang-Yang Wang, Li-Ping Zou, Kai-Feng Xu, et al.
Brain Pathology (Zurich, Switzerland)|December 14, 2020
A novel temporal-predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS-TDPJorge J Llibre-Guerra, Suzee E Lee, Claudia K Suemoto, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Plos One|December 25, 2015
Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell ContractilityYing-Ju Lin, Tsung-Jung Ho, Yi-Chun Yeh, et al.
Journal of Global Health|August 11, 2025
An investigation into the impact of family integrated care on extrauterine growth restriction at discharge in very low birth weight infants: a multi-centre studyMeng-Fan Qiu, Yi Zhang, Ying-Zi Tang, et al.
Neurology|January 6, 2026
Development and International Validation of a Novel Imaging-Based Risk Score (IsCHEMiA) for the Prediction of Poststroke EpilepsyWilliam C Y Leung, Tomotaka Tanaka, Rachel A Donahue, et al.
The Journal of Infection|May 28, 2021
Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance studyYaoju Tan, Yunfeng Deng, Xiaofeng Yan, et al.
NPJ Genomic Medicine|June 29, 2026
Systematic evaluation of long-read and short-read sequencing in neurological disorders diagnosis: a direct comparison study of 310 patientsDream Lok Sze Chan, Helen Ying Fung Tam, Amy Hin Yan Tong, et al.
Pageof 71

Showing results (691-700 of 701) with videos related to

Sort By:
Pageof 71
Antimicrobial Agents and Chemotherapy|January 31, 2018
Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in ChinaQingfeng Wang, Yu Pang, Wei Jing, et al.
Orphanet Journal of Rare Diseases|August 15, 2024
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysisYang-Yang Wang, Li-Ping Zou, Kai-Feng Xu, et al.
Brain Pathology (Zurich, Switzerland)|December 14, 2020
A novel temporal-predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS-TDPJorge J Llibre-Guerra, Suzee E Lee, Claudia K Suemoto, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Plos One|December 25, 2015
Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell ContractilityYing-Ju Lin, Tsung-Jung Ho, Yi-Chun Yeh, et al.
Journal of Global Health|August 11, 2025
An investigation into the impact of family integrated care on extrauterine growth restriction at discharge in very low birth weight infants: a multi-centre studyMeng-Fan Qiu, Yi Zhang, Ying-Zi Tang, et al.
Neurology|January 6, 2026
Development and International Validation of a Novel Imaging-Based Risk Score (IsCHEMiA) for the Prediction of Poststroke EpilepsyWilliam C Y Leung, Tomotaka Tanaka, Rachel A Donahue, et al.
The Journal of Infection|May 28, 2021
Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance studyYaoju Tan, Yunfeng Deng, Xiaofeng Yan, et al.
NPJ Genomic Medicine|June 29, 2026
Systematic evaluation of long-read and short-read sequencing in neurological disorders diagnosis: a direct comparison study of 310 patientsDream Lok Sze Chan, Helen Ying Fung Tam, Amy Hin Yan Tong, et al.
Pageof 71